Growing cells outside the body, et al

[Guest guest]

As an aside, I am wondering what happened to the message board, if you look at

the chart, you will note that our posts have fallen considerably. Last year at

this time, there were 540 messages posted, this year, so far only 240. It can't

be for lack of news, or is it summer lethargy? LOL

___________________________________

An understanding of the factors that govern migration of blood stem cells might

lead to improved treatment of leukemia, a cancer that affects circulating white

blood cells. The findings also have implications for culturing

infection-fighting immune cells outside the body, where they could be

temporarily held in storage during chemotherapy and other treatments which

suppress the immune system. Moreover, the findings could contribute to a

strategy for growing large quantities of red blood cells in laboratory dishes

outside the body, to reduce the need for blood donations.

http://www.medicalnewstoday.com/articles/143817.php

______________________________

Disease Page Definitions (Glossary)

http://www.leukemia-lymphoma.org/all_page.adp?item_id=464236

______________________________

What is pallative care?

http://www.news-medical.net/health/Palliative-Care-What-is-Palliative-Care.aspx

______________________________

June 7, 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation BioSante

Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for

GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the

FDA's Office of Orphan Products Development. Orphan drug designation, as granted

by the U.S. Orphan Drug Act, is for a product to treat a rare disease or

condition that affects fewer than 200,000 people in the U.S. Orphan drug

designation qualifies the sponsor of the product for tax credits and seven years

of marketing exclusivity, among other benefits.

http://www.news-medical.net/news/20100607/BioSantes-GVAX-CML-Vaccine-granted-FDA\

-Orphan-Drug-designation.aspx

__________________________

Catalytic Activity of AblT315I Is Inhibited by SGX393.

Application of x-ray crystallographic lead discovery and structure-guided

optimization identified 1 [supporting information (SI) Fig. 6A ] as an inhibitor

of Abl and AblT315I, binding an active conformation of the Abl kinase domain (SI

Fig. 6). Further development yielded SGX393, an inhibitor of native Bcr-Abl and

most imatinib-resistant mutants, including Bcr-AblT315I, whose structure will be

reported elsewhere. Recently, the crystal structure of AblT315I in complex with

a pyrrolopyridine inhibitor related to 1 was reported (17).

http://www.pnas.org/content/105/14/5507.full

________________________________

The 'gatekeeper mutation' T315I is responsible for a general resistance to small

molecules. It seems not only to decrease the affinity for kinase inhibitors, but

to also confer additional features to the leukemogenic potential of BCR/ABL. To

determine the role of T315I in resistance to the inhibition of oligomerization

and in the leukemogenic potential of BCR/ABL, we investigated its influence on

loss-of-function mutants with regard to the capacity to mediate factor

independence.

More at the cited website. Original article published April 16, 2009

http://www.nature.com/leu/journal/v23/n9/abs/leu200969a.html

_______________________________

August 2010 - Separating the science from the mythology on food allergies:

Numerous genes are involved in innate and adaptive immunity and these have been

modified over millions of years. During this evolution, the mucosal immune

system has developed two anti-inflammatory strategies: immune exclusion by the

use of secretory antibodies to control epithelial colonization of microorganisms

and to inhibit the penetration of potentially harmful agents; and

immunosuppression to counteract local and peripheral hypersensitivity against

innocuous antigens, such as food proteins. (more at website)

http://www.nature.com/nrgastro/journal/v7/n7/full/nrgastro.2010.80.html

___________________________________

FYI,

Lottie Duthu